Healthcare WebWire
Share
in Instagram

Subcutaneous Biologics Market Set to Surge: A Self-Care Revolution in Therapeutics

Download sample Download Sample

Market Overview

The global subcutaneous biologics market is on a strong growth trajectory, projected to expand from USD 1.89 billion in 2024 to USD 5.37 billion by 2034, marking a robust CAGR of 11.09%. This surge is largely driven by the increasing demand for self-administered therapies, patient-friendly delivery methods, and advancements in biologics and drug delivery technologies.

What are Subcutaneous Biologics?

Biologics are complex therapies derived from living cells, including monoclonal antibodies, vaccines, gene therapies, and more. These are administered either intravenously (IV) or subcutaneously (SC). Subcutaneous administration involves injecting the drug directly into the fatty tissue beneath the skin, allowing for slower and sustained absorption, making it a preferred route for many therapies.

Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5726

Key Market Highlights

  • 2024 Market Size: USD 1.89 Billion

  • 2034 Forecast: USD 5.37 Billion

  • Growth Rate (2025–2034): 11.09% CAGR

  • Regional Leader: North America

  • Fastest-Growing Region: Asia-Pacific

Segmental Insights

By Biologic Type:

  • Dominant in 2024: Antibodies led the market revenue.

  • Emerging Leader: Nucleotides are anticipated to witness rapid growth.

By Administration Method:

  • Top Contributor in 2024: Injections

  • Fast-Growing Segment: Infusion methods are gaining traction due to ease of use and patient compliance.

By Therapeutic Area:

  • Leading Segment: Autoimmune disorders

  • Highest Projected Growth: Oncological disorders due to increasing cancer cases and advancements in immunotherapy.

Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5726

1. Rising Preference for Self-Administration

Subcutaneous delivery is revolutionizing patient care by enabling home-based treatment. It eliminates the need for clinical visits, improves treatment adherence, and promotes a more patient-centric approach.

2. Technological Collaborations

  • Novartis & Lindy Biosciences (Aug 2024): Partnered to develop single-dose injectables using microglassification technology.

  • OneSource & Bhami’s Research Laboratory (Aug 2024): Collaborated on HILOPROO technology to reduce viscosity for high-concentration biologics.

AI Empowering Drug Delivery

Artificial Intelligence (AI) is increasingly being embedded into smart drug delivery systems. AI can:

  • Automate dose measurement and reminders

  • Ensure regulatory compliance

  • Provide real-time insights to healthcare professionals

  • Enhance personalized dosing and medication adherence

If you have any questions, please feel free to contact us at [email protected]

FAQ's

Answer : The global elastomers market size was reached at USD 92 billion in 2021 and it is anticipated to rake around USD 165 billion by 2030.

Answer : The global elastomers market is expected to drive growth at a CAGR of 6.71% over the forecast period 2022 to 2030.

Answer : The major players operating in the elastomers market are BASF SE (Germany), E. I. du Pont de Nemours and Company (U.S.), Lanxess AG (Germany), The Dow Chemical Company (U.S.), JSR Corporation (Japan).

Answer : The demand for elastomers is increasing for the heating, ventilation and air conditioning industry. The demand for elastomers is increasing for producing the construction industry materials like the coatings, tubes, adhesives and all the other materials are driving the market growth.

Answer : Asia Pacific region will lead the global elastomers market over the next ten years.

Ready to Transform Your Financial Management?

We are committed to providing the best healthcare services tailored to your needs We are committed to providing the best healthcare services tailored

Talk to an Analyst Learn more
Financial Management